Avalglucosidase Alfa Improves Breathing, Mobility in Late-onset Patients in Phase 3 Trial
News
Avalglucosidase alfa, an investigational next-generation enzyme replacement therapy (ERT), leads to clinically meaningful improvements in respiratory muscle strength and mobility in children and adults with late-onset Pompe disease (LOPD), according ... Read more